The overall objective of this proposal is to elucidate the cellular mechanisms underlying the late phase of ischemic preconditioning (PC). The PI will attempt to develop a unifying pathogenetic paradigm applicable both to late PC against stunning and to late PC against infarction. The fundamental hypothesis is that, in both cases, NO plays a pivotal role, acting initially as the trigger and subsequently as the mediator of the protection (NO hypothesis of late PC). The PI proposes that NO formed during the initial PC stimulus activates a PKC-and NF-VB-dependent signal transduction cascade that culminates in increased expression of NOS, which then mediates the protection of late PC. Two different, but complementary, models (conscious rabbits and genetically-manipulated mice) will be used to arrive at conclusions that are definitive and, at the same time, physiologically relevant. A broad multidisciplinary approach will be used that will combine diverse techniques (integrative physiology, protein chemistry, cell biology, molecular biology, gene targeting and transgenesis) and will integrate genetic information at the molecular level with physiological information at the conscious animal level. The role of PKC as a critical effector of NO-initiated signaling in vivo will be directly investigated using isoform-selective assays of PKC in the presence or absence of NOS inhibitors or NO donors. The role of NF-VB as a key step in the signal transduction cascade responsible for late PC will be systematically evaluated by selective in vivo inhibition in conscious rabbits and selective gene manipulations in mice overexpressing a mutant lVBB that produces transdominant repression of NF-VB. The specific NOS isoforms responsible for initiating as well as mediating late PC will be identified both in conscious rabbits and in mice. The roles of iNOS, eNOS, and nNOS in rabbits will be interrogated by determining whether the changes in these isoforms after PC correlate with the time-course of protection and with the tissue levels of NOx and cGMP in the presence or absence of selective iNOS inhibitors. The posttranslational modulation of iNOS after PC will be explored by examining the effect of tyrosine kinase inhibitors on NOS activity and protein phosphorylation. The role of each individual NOS isoform in triggering vis-a-vis mediating late PC will be conclusively established by targeted disruption of the iNOS, eNOS, and nNOS gene in mice subjected to ischemic PC. A wide range of transgenic overexpressions of individual NOS isoforms will be examined to delineate in quantitative terms the relationship between NOS activity and cardioprotection. This proposal should produce important new insights into the molecular mechanisms of late PCA and into the role of NO in cardiovascular pathophysiology in general. Elucidation of the mechanism of late PC should facilitate the development of drugs that duplicate its powerful cardioprotective effects.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL043151-10
Application #
6030595
Study Section
Cardiovascular and Renal Study Section (CVB)
Project Start
1989-08-01
Project End
2003-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
10
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Louisville
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Louisville
State
KY
Country
United States
Zip Code
40292
Li, Qianhong; Guo, Yiru; Ou, Qinghui et al. (2009) Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway. Circulation 120:1222-30
Zuba-Surma, Ewa K; Kucia, Magdalena; Dawn, Buddhadeb et al. (2008) Bone marrow-derived pluripotent very small embryonic-like stem cells (VSELs) are mobilized after acute myocardial infarction. J Mol Cell Cardiol 44:865-73
Wang, Guang-Wu; Guo, Yiru; Vondriska, Thomas M et al. (2008) Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCepsilon signaling and cardioprotection. J Mol Cell Cardiol 44:1016-22
Dawn, Buddhadeb; Xuan, Yu-Ting; Guo, Yiru et al. (2004) IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 64:61-71
Shinmura, Ken; Nagai, Maiko; Tamaki, Kayoko et al. (2004) Gender and aging do not impair opioid-induced late preconditioning in rats. Basic Res Cardiol 99:46-55
Wang, Yang; Kodani, Eitaro; Wang, Jianxun et al. (2004) Cardioprotection during the final stage of the late phase of ischemic preconditioning is mediated by neuronal NO synthase in concert with cyclooxygenase-2. Circ Res 95:84-91
Dawn, Buddhadeb; Guo, Yiru; Rezazadeh, Arash et al. (2004) Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol 37:51-61
Zhang, Jun; Ping, Peipei; Wang, Guang-Wu et al. (2004) Bmx, a member of the Tec family of nonreceptor tyrosine kinases, is a novel participant in pharmacological cardioprotection. Am J Physiol Heart Circ Physiol 287:H2364-6
Tang, Xian-Liang; Xuan, Yu-Ting; Zhu, Yanqing et al. (2004) Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol Heart Circ Physiol 286:H1273-80
Leesar, Massoud A; Stoddard, Marcus F; Xuan, Yu-Ting et al. (2003) Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans. J Am Coll Cardiol 42:437-45

Showing the most recent 10 out of 125 publications